GlassScriptPhysician profile
Jeffery D Morton
NPI 1497799605
$2,844.41
in general payments reported to CMS, 2019-2025
48 companies · $2,297 in 2025
The $2,297 reported for 2025 was more than what 91% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.79 · 2022: $92.64 · 2023: $52.11 · 2024: $386 · 2025: $2,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,734.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $291.74 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Astrazeneca Pharmaceuticals LP | $204.34 | 2023-2025 | Lynparza, Imfinzi |
| Genmab U.S., INC. | $180.14 | 2025 | Epkinly |
| Daiichi Sankyo INC. | $141.51 | 2022-2025 | Enhertu, Vanflyta |
| Novartis Pharmaceuticals Corporation | $136.91 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $134.71 | 2024-2025 | Provenge |
| Janssen Biotech, INC. | $120.11 | 2025 | Rybrevant, Erleada, Tecvayli |
| Bayer Healthcare Pharmaceuticals INC. | $112.26 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $96.78 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Stemline Therapeutics INC. | $88.73 | 2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $82.44 | 2024-2025 | Fruzaqla, Iclusig, Ninlaro |
| Geron Corporation | $75.31 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $64.90 | 2025 | Libtayo, Lynozyfic |
| Caris Mpi, INC. | $60.95 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $60.28 | 2025 | Tecentriq, Phesgo |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.